Newsroom

New Director Elected to Sangart's Board

SAN DIEGO, CA (February 01, 2002) – Sangart, Inc., a biopharmaceutical company focused on the development of novel hemoglobin-based red-cell substitutes, announced today the election of Dr. Curtis Scribner, formerly Chief of the Blood Division at the FDA, to their Board of Directors.

Curtis Scribner, M.A., M.B.A. Dr. Scribner received his baccalaureate degree from Grinnell College, his medical degree from the University of Colorado College of Medicine, and an M.B.A. from the University of Maryland. Dr. Scribner is formally trained in immunology and rheumatology, having held post-doctoral research positions at both the University of Nebraska, where he was also Chief Medical Resident, and the National Institutes of Health, Center for Disease Control. He was also principal clinical investigator for a number of field studies in infectious diseases in Sierra Leone, West Africa. From 1987 until 1997, Dr. Scribner served in positions of increasing responsibility at the U.S. Food and Drug Administration in the Center for Biologic Evaluation and Research. Dr. Scribner was Deputy Director of the Office of Blood Research and Review. In this capacity he was responsible for the activities of three Divisions, with scientific, medical and regulatory oversight of blood and plasma products and devices, particularly those related to hepatitis B, hepatitis C, and HIV. Subsequently Dr. Scriber served as Chief Regulatory Scientist for Quintiles Consulting where his responsibilities ranged broadly and included responsibility for filing marketing applications for drugs, biologics, and devices. While at Quintiles, Dr. Scribner first began to consult with Sangart on the FDA regulatory process. Dr. Scribner has advised and represented companies headquartered in Asia, Europe, and the United States. Dr. Scribner currently sets regulatory policy and directs worldwide regulatory activities for BioMedicines, Inc, located in Alameda, California.

About Sangart, Inc.

Sangart, Inc. is a privately held biopharmaceutical company with offices located in San Diego, California, and Stockholm, Sweden. Sangart was founded in 1998 by Dr. Robert M. Winslow, to develop and commercialize products and technologies related to artificial blood. Dr. Winslow has had 30 years of experience in the study of hemoglobin and hemoglobin-based blood substitutes, and is considered to be one of the leading scientists in the field. The company currently has twenty-three full-time employees. The core technology is based on the understanding of hemoglobin’s capability to transport oxygen. This has laid the groundwork for the company’s business concept of developing products that can temporarily substitute for blood transfusions during surgery and injuries involving the loss of blood.

Hemospan®

The key breakthroughs in the development of Sangart’s lead product, Hemospan®, were the understanding of the mechanisms of vasoconstriction, and the development of simplified production methods that make the final product cost-effective. Preclinical research has shown Hemospan® to be remarkably free of toxicity, and more effective than blood in head-to-head comparisons. Preclinical Studies have been completed in the United States and Sweden.

To learn more about Sangart or Hemospan®, please visit www.sangart.com